REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, Inc., a women’s healthcare company that has developed a minimally invasive device for the treatment of symptomatic uterine fibroids, announced today that it has received CE Mark approval for its next generation VizAblate® System. The CE Mark enables Gynesonics to market its proprietary VizAblate System throughout the European Union.
Help employers find you! Check out all the jobs and post your resume.
